Display options
Cite
Capron M, Béghin L, Leclercq C, et al. Safety of P28GST, a Protein Derived from a Schistosome Helminth Parasite, in Patients with Crohn's Disease: A Pilot Study (ACROHNEM). J Clin Med. 2019;9(1)doi: 10.3390/jcm9010041.
Capron, M., Béghin, L., Leclercq, C., Labreuche, J., Dendooven, A., Standaert, A., Delbeke, M., Porcherie, A., Nachury, M., Boruchowicz, A., Dupas, J. L., Fumery, M., Paupard, T., Catteau, S., Deplanque, D., Colombel, J. F., & Desreumaux, P. (2019). Safety of P28GST, a Protein Derived from a Schistosome Helminth Parasite, in Patients with Crohn's Disease: A Pilot Study (ACROHNEM). Journal of clinical medicine, 9(1), . https://doi.org/10.3390/jcm9010041
Capron, Monique, et al. "Safety of P28GST, a Protein Derived from a Schistosome Helminth Parasite, in Patients with Crohn's Disease: A Pilot Study (ACROHNEM)." Journal of clinical medicine vol. 9,1 (2019). doi: https://doi.org/10.3390/jcm9010041
Capron M, Béghin L, Leclercq C, Labreuche J, Dendooven A, Standaert A, Delbeke M, Porcherie A, Nachury M, Boruchowicz A, Dupas JL, Fumery M, Paupard T, Catteau S, Deplanque D, Colombel JF, Desreumaux P. Safety of P28GST, a Protein Derived from a Schistosome Helminth Parasite, in Patients with Crohn's Disease: A Pilot Study (ACROHNEM). J Clin Med. 2019 Dec 24;9(1). doi: 10.3390/jcm9010041. PMID: 31878146; PMCID: PMC7019330.
Copy Download .nbib Format: NLM
Share it on

J Clin Med. 2019 Dec 24;9(1). doi: 10.3390/jcm9010041.

Safety of P28GST, a Protein Derived from a Schistosome Helminth Parasite, in Patients with Crohn's Disease: A Pilot Study (ACROHNEM).

Journal of clinical medicine

Monique Capron, Laurent Béghin, Céline Leclercq, Julien Labreuche, Arnaud Dendooven, Annie Standaert, Marie Delbeke, Adeline Porcherie, Maria Nachury, Arnaud Boruchowicz, Jean-Louis Dupas, Mathurin Fumery, Thierry Paupard, Sylviane Catteau, Dominique Deplanque, Jean-Frederic Colombel, Pierre Desreumaux

Affiliations

  1. U995-LIRIC, Lille Inflammation Research International Center, Univ. Lille, Inserm, CHU Lille, F-59000 Lille, France.
  2. CIC 1403, Centre d'Investigation Clinique, Univ. Lille, Inserm, CHU Lille, F-59000 Lille, France.
  3. Direction de la Recherche et de l'Innovation, CHU Lille, F-59000 Lille, France.
  4. EA 2694-Santé Publique: épidémiologie et Qualité des Soins, Univ. Lille, CHU Lille, F-59000 Lille, France.
  5. Par'Immune, Eurasante, F-59120 Loos lez Lille, France.
  6. Service des Maladies de l'Appareil Digestif, Unité de Recherche Clinique, Centre Hospitalier de Valenciennes, F-59300 Valenciennes, France.
  7. Service d'Hépato-Gastro-Entérologie, CHU Amiens Picardie, F-80054 Amiens, France.
  8. Service d'Hépato-Gastro-Entérologie, Unité de Recherche Clinique, Centre Hospitalier de Dunkerque, F-59385 Dunkerque, France.
  9. Service d'Hépato-Gastro-Entérologie, Unité de Recherche Clinique, Centre Hospitalier de Boulogne sur Mer, F-62200 Boulogne Sur Mer, France.
  10. Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.

PMID: 31878146 PMCID: PMC7019330 DOI: 10.3390/jcm9010041

Abstract

Despite the development of novel therapies, inflammatory bowel diseases remain an innovative treatment challenge. Helminth therapy is a new promising approach, and a key issue is the identification of helminth-derived anti-inflammatory mediators. P28 glutathione-S-transferase (P28GST), a protein derived from schistosomes, a trematode parasitic helminth, was shown to reduce intestinal inflammation in experimental colitis by down-regulating the Th1/Th17 response. In this multicenter, open-label, pilot Phase 2a study, we evaluated the safety of P28GST administered to patients with mild Crohn's disease (CD). We enrolled 10 patients with a baseline Crohn's disease activity index (CDAI) value <220. Eight patients received two to three subcutaneous injections of recombinant P28GST with adjuvant. This three-month treatment was followed by a nine-month monitoring period. The primary endpoints were the monthly rate and seriousness of adverse events (AEs). Secondary endpoints were clinical recurrence, assessed with the CDAI as well as the levels of immunologic and inflammatory blood and tissue markers. The most common AEs were local or regional events at the injection site and gastrointestinal disorders. At three months after the first injection, CDAI scores and blood calprotectin levels decreased in parallel. These results indicate that P28GST showed promise as a safe and new therapeutic option for treating CD.

Keywords: Crohn’s disease; Crohn’s disease activity index; P28GST; calprotectin; helminth protein; safety

References

  1. Lancet Infect Dis. 2014 Nov;14(11):1150-1162 - PubMed
  2. Clin Med Insights Gastroenterol. 2015 May 06;8:29-44 - PubMed
  3. World J Gastroenterol. 2017 Sep 7;23(33):6009-6015 - PubMed
  4. J Crohns Colitis. 2017 Apr 1;11(4):390-399 - PubMed
  5. Aliment Pharmacol Ther. 2019 Feb;49(3):265-276 - PubMed
  6. Therapie. 1985 Mar-Apr;40(2):111-8 - PubMed
  7. Perspect Clin Res. 2010 Jul;1(3):106-9 - PubMed
  8. PLoS One. 2018 Dec 28;13(12):e0209681 - PubMed
  9. Clin Gastroenterol Hepatol. 2016 Jan;14(1):71-9 - PubMed
  10. World J Gastroenterol. 2016 May 28;22(20):4802-11 - PubMed
  11. PLoS Negl Trop Dis. 2018 Dec 7;12(12):e0006968 - PubMed
  12. Gut. 2005 Jan;54(1):87-90 - PubMed
  13. Gastroenterology. 1979 Oct;77(4 Pt 2):843-6 - PubMed
  14. Gastroenterology. 2005 Apr;128(4):825-32 - PubMed
  15. Mucosal Immunol. 2016 Mar;9(2):322-35 - PubMed
  16. J Immunol Res. 2014;2014:459048 - PubMed
  17. J Crohns Colitis. 2013 Dec;7(12):e678-83 - PubMed
  18. World J Gastroenterol. 2017 Nov 7;23(41):7387-7396 - PubMed
  19. PLoS Negl Trop Dis. 2012;6(7):e1704 - PubMed
  20. Cells. 2019 Jun 12;8(6): - PubMed
  21. Nat Rev Immunol. 2016 Aug;16(8):524-32 - PubMed
  22. J Clin Med Res. 2018 Aug;10(8):609-614 - PubMed

Publication Types

Grant support